<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948918</url>
  </required_header>
  <id_info>
    <org_study_id>005/e3</org_study_id>
    <nct_id>NCT04948918</nct_id>
  </id_info>
  <brief_title>Distal Renal Denervation to Prevent Renal Function Decline in Patients With T2DM and Hypertension</brief_title>
  <acronym>REFRAIN</acronym>
  <official_title>Efficacy of Distal Renal Denervation for Preventing Decline in Renal Function in Patients With Type 2 Diabetes Mellitus and Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the hypothesis that distal renal denervation (RDN) may delay&#xD;
      or prevent the progressive decline of renal function in patients with type 2 diabetes&#xD;
      mellitus and hypertension&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: Diabetes mellitus and hypertension are two major causes of chronic&#xD;
      kidney disease (CKD) that starts as subclinical decline in renal function that silently&#xD;
      progresses to symptomatic advanced stages associated with irreversible significant damage of&#xD;
      the kidney structure. Recent major improvements in pharmacotherapy of hypertension and&#xD;
      diabetes have substantially reduced the prevalence of cardiovascular complications, yet, the&#xD;
      frequency of CKD remains largely unchanged. Renal denervation is a new minimally invasive&#xD;
      method to create regional blockade of the renal sympathetic nerves that is currently used as&#xD;
      non-pharmacological therapy of hypertension. The CKD is likewise mediated by overactivity of&#xD;
      renal sympathetic system so that RDN has strong potential to prevent development or&#xD;
      progression of CKD. The new anatomically optimized distal RDN may have additional benefit in&#xD;
      this regard. Denervation of the distal vessels involved in tonic regulation of renal blood&#xD;
      should cause a significant drop in renal vascular resistance and proportional increase in&#xD;
      blood and oxygen supply to the kidney preventing/reducing chronic hypoxia of renal tissue&#xD;
      that is major mechanism of CKD. The aim of this study is to prove the aforementioned concept.&#xD;
      For this purpose the eligible patients with type 2 diabetes mellitus and hypertension will&#xD;
      undergo distal renal denervation performed using dedicated radiofrequency catheter Symplicity&#xD;
      Spyral. The changes in the kidney function and structure as well as BPs (office and&#xD;
      ambulatory) will be assessed at baseline, 6 and 12 months post-procedure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2020</start_date>
  <completion_date type="Anticipated">September 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in estimated glomerular filtration rate renal function (eGFR)</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>eGFR calculated using CKD-EPI formula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR</measure>
    <time_frame>from baseline 12 months</time_frame>
    <description>eGFR calculated using CKD-EPI formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office blood pressure levels (systolic/diastolic)</measure>
    <time_frame>from baseline to 6 months and 12 months</time_frame>
    <description>Blood pressure measurement performed by physician in office</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ambulatory 24-hour blood pressure levels (24-h mean, daytime, nighttime; systolic/diastolic)</measure>
    <time_frame>from baseline to 6 and 12 months</time_frame>
    <description>Mean values for respective periods calculated from ambulatory blood pressure monitoring performed using automatic measurement device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cystatin C levels</measure>
    <time_frame>from baseline to 6 and 12 months</time_frame>
    <description>blood analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipocalin 2 (NGAL) levels</measure>
    <time_frame>from baseline to 6 and 12 months</time_frame>
    <description>blood analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour urinary albumin excretion</measure>
    <time_frame>from baseline to 6 and 12 months</time_frame>
    <description>urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the cortical and medullary volume of the kidneys and their ratio according to MRI</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Cortical and medullary volume measured using magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic significance of baseline HbA1c value with regard to change in eGFR</measure>
    <time_frame>from baseline to 6 and 12 months</time_frame>
    <description>Will be assessed from multiple regression model of linear dependence of change in eGFR on a number of independent variables including in addition to HbA1c also age, sex, baseline eGFR, and 24-h ambulatory systolic BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal resistive index in a trunk</measure>
    <time_frame>from baseline to 6 and 12 months</time_frame>
    <description>resistive index calculated using blood flow velocity on Doppler ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peak linear blood flow velocity in the trunk and in segmental renal arteries</measure>
    <time_frame>from baseline to 6 and 12 months</time_frame>
    <description>blood flow velocity assessed by Doppler flowmetry in the trunk of the renal arteries and in segmental renal arteries using averaged values</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Distal renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The arm comprises patients undergoing distal bilateral radiofrequency renal denervation performed using Symplicity Spyral renal denervation system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anatomically optimized distal renal denervation</intervention_name>
    <description>Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter</description>
    <arm_group_label>Distal renal denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent of participation in the study;&#xD;
&#xD;
          -  systolic BP &gt; 140 or diastolic BP &gt; 90 mm Hg;&#xD;
&#xD;
          -  type 2 diabetes mellitus (glucose tolerance test &gt; 11.0 mmol/l, HbA1c&gt;6,5%);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary hypertension;&#xD;
&#xD;
          -  type 1 diabetes mellitus;&#xD;
&#xD;
          -  acute renal failure;&#xD;
&#xD;
          -  traumatic kidney injury;&#xD;
&#xD;
          -  toxic kidney injury;&#xD;
&#xD;
          -  CKD G4 and G5 according to the KDIGO 2012;&#xD;
&#xD;
          -  infectious diseases requiring active antibacterial and/or antiviral therapy;&#xD;
&#xD;
          -  other severe diseases and conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alla Falkovskaya, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alla Falkovskaya, PhD</last_name>
    <phone>+7-913-884-52-69</phone>
    <email>alla@cardio-tomsk.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Falkovskaya, PhD</last_name>
      <phone>+7-913-884-52-69</phone>
      <email>alla@cardio-tomsk.ru</email>
    </contact>
    <investigator>
      <last_name>Stanislav Pekarskiy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>kidney</keyword>
  <keyword>renal function</keyword>
  <keyword>denervation</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

